Comparison of diffusion-weighted imaging and [123I]IBZM-SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease

Mov Disord. 2004 Dec;19(12):1438-45. doi: 10.1002/mds.20229.

Abstract

Both dopamine D2 receptor (D2R) binding single-photon emission computed tomography (SPECT) with [123I]iodobenzamide (IBZM) and diffusion-weighted imaging (DWI) have been shown to contribute to the differential diagnosis of patients with the Parkinson variant of multiple system atrophy (MSA-P) and Parkinson's disease (PD). We aimed to compare these two routinely available functional imaging modalities in differentiating patients with MSA-P from PD. For this purpose, results obtained by DWI and IBZM-SPECT were intraindividually compared in a cross-sectional study of 15 MSA-P and 17 PD patients matched for age and disease duration. The activity ratios of striatal to frontal cortex uptake (S/FC ratio) were used as a semiquantitative measure of the relative density of basal ganglia dopamine receptors labeled by IBZM. Regional apparent diffusion coefficients (rADC) were determined in the striatum. MSA-P patients had significantly lower S/FC ratios and significantly higher striatal rADCs than both PD patients and healthy volunteers. There were no significant differences in S/FC ratios and striatal rADC between PD patients and healthy volunteers. Sensitivity of IBZM-SPECT versus DWI for the differentiation of MSA-P from PD was 80% versus 93%, specificity 71% versus 100%, the predictive accuracy 75% versus 97%, the positive predictive value 71% versus 100%, and the negative predictive value 80% versus 94%. Striatal rADCs had a significant higher overall predictive accuracy than D2R binding with IBZM. In summary, our data suggest that DWI may be more accurate compared to IBZM-SPECT in the differential diagnosis of MSA-P versus PD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Basal Ganglia / blood supply
  • Benzamides
  • Contrast Media
  • Corpus Striatum / blood supply*
  • Cross-Sectional Studies
  • Diffusion Magnetic Resonance Imaging*
  • Follow-Up Studies
  • Frontal Lobe / blood supply*
  • Humans
  • Middle Aged
  • Multiple System Atrophy / complications*
  • Multiple System Atrophy / diagnosis*
  • Multiple System Atrophy / diagnostic imaging
  • Parkinson Disease / complications*
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / diagnostic imaging
  • Predictive Value of Tests
  • Pyrrolidines
  • Sensitivity and Specificity
  • Tomography, Emission-Computed, Single-Photon*

Substances

  • Benzamides
  • Contrast Media
  • Pyrrolidines
  • 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide